Truvestments Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$313K Sell
2,247
-31
-1% -$4.34K 0.06% 257
2025
Q4
$280K Buy
2,278
+261
+13% +$31.7K 0.05% 253
2025
Q3
$224K Sell
2,017
-532
-21% -$60.5K 0.04% 277
2025
Q2
$283K Sell
2,549
-64
-2% -$6.81K 0.06% 221
2025
Q1
$293K Buy
2,613
+1,010
+63% +$104K 0.06% 207
2024
Q4
$148K Buy
1,603
+104
+7% +$9.36K 0.04% 247
2024
Q3
$126K Buy
+1,499
New +$114K 0.03% 258
2024
Q2
Sell
-1,476
Closed -$108K 407
2024
Q1
$108K Buy
1,476
+85
+6% +$6.54K 0.04% 291
2023
Q4
$113K Buy
1,391
+775
+126% +$60.3K 0.05% 248
2023
Q3
$46.2K Sell
616
-14
-2% -$1.08K 0.02% 296
2023
Q2
$48.5K Buy
630
+175
+38% +$14K 0.02% 296
2023
Q1
$37.8K Sell
455
-237
-34% -$19.6K 0.02% 318
2022
Q4
$59.4K Buy
692
+37
+6% +$2.93K 0.03% 287
2022
Q3
$40K Sell
655
-199
-23% -$12.5K 0.03% 271
2022
Q2
$53K Buy
+854
New +$52.9K 0.03% 251
2022
Q1
Sell
-849
Closed -$62K 317
2021
Q4
$62K Buy
849
+457
+117% +$31.5K 0.03% 244
2021
Q3
$27K Buy
392
+2
+0.5% +$141 0.01% 298
2021
Q2
$27K Sell
390
-1,894
-83% -$126K 0.01% 300
2021
Q1
$148K Buy
2,284
+2
+0.1% +$129 0.08% 181
2020
Q4
$132K Buy
2,282
+564
+33% +$34K 0.09% 176
2020
Q3
$109K Buy
1,718
+33
+2% +$2.29K 0.1% 145
2020
Q2
$129K Sell
1,685
-346
-17% -$26.5K 0.13% 124
2020
Q1
$151K Buy
+2,031
New +$140K 0.19% 102
2019
Q4
Sell
-1,627
Closed -$103K 312
2019
Q3
$103K Buy
1,627
+2
+0.1% +$131 0.07% 175
2019
Q2
$110K Sell
1,625
-128
-7% -$8.42K 0.07% 174
2019
Q1
$114K Buy
+1,753
New +$117K 0.09% 147
2018
Q3
$210K Buy
+2,726
New +$206K 0.1% 173

Other funds holding GILD

Truvestments Capital's GILD Position: Q1 2026 in Review

Truvestments Capital reduced its Gilead Sciences (GILD) stake by 1.4% in Q1 2026, selling an estimated $4.34K and leaving 2,247 shares worth $313K. The position accounts for 0.06% of the portfolio, ranked #257.

Truvestments Capital first reported a position in GILD in Q3 2018 and has held it in 27 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Truvestments Capital held 2,247 shares of Gilead Sciences worth $313K as of Q1 2026.
  • Truvestments Capital sold 31 Gilead Sciences shares in Q1 2026, an estimated $4.34K.
  • Gilead Sciences made up 0.06% of Truvestments Capital's portfolio in Q1 2026, its #257 holding.
  • Truvestments Capital first reported a position in Gilead Sciences in Q3 2018 and has held it in 27 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.